Latest posts
-
Evidence-Based Brand Value: The GLP-1 Test for the Future of Indian Pharma Marketing
Can brand preference increasingly be earned by demonstrating value rather than merely promoting it? Several themes explored in my earlier articles now appear to converge on one important question for Indian pharma. The…
-
When Systems Create Blind Spots: The Hidden Risk in Indian Pharma’s Growing Complexity
India’s pharmaceutical industry is becoming more sophisticated, interconnected and complex than ever before. A single medicine may now involve API suppliers, formulation developers, technology partners, contract…
-
Beyond New Molecules: Why India Must Broaden Its Understanding of Pharmaceutical Innovation
For more than two decades, the conversation on pharmaceutical patents in India has revolved around a familiar set of themes — product patents, Section 3(d) of the Patents Act, evergreening, compulsory licensing, and the…
-
From Regulatory Reform to Global Competitiveness – Where Does Indian Pharma Go from Here?
Executive Summary: On July 30, 2026, Reuters reported that India’s pharmaceutical quality initiative—launched in response to quality concerns that emerged in late 2022—had resulted in regulatory action against…
-
The Age of Accountability: What India’s Pharmaceutical Industry Must Learn from a Public Movement
Recent policy initiatives suggest the Government is responding to changing public expectations. Should the pharmaceutical industry do the same—for the sake of patients? Executive Summary: India is witnessing a profound…
-
The Next Frontier in Healthcare Isn’t Just Better Medicines – It’s Better Decisions
How a recent Government initiative could quietly reshape the future of healthcare, pharmaceutical innovation and patient care in India Executive Summary: On 17 February 2026, the Government of India launched…
-
When a Medicine’s Brand Name Becomes a Patient Safety Issue: What CDSCO’s Draft Proposal Signals for the Future of Indian Pharma
Can a medicine’s brand name save—or endanger—a patient’s life? At first glance, the question seems counterintuitive. Medicines save lives because of their pharmacology, not because of the names printed on their…
-
The New License to Compete: Why Indian Pharma Must Rethink the Rules of Competition
Executive Summary: For more than four decades, Indian pharmaceutical companies have built a formidable global reputation through affordable manufacturing, process innovation, regulatory excellence and an unwavering…
-
Understanding the Multinational Perspective: Legitimate Concerns, but Not the Complete Answer (Part: III)
No discussion on pharmaceutical innovation in India is complete without acknowledging why multinational research-based pharmaceutical companies continue to advocate for stronger intellectual property protection. Viewed…
-
How Does India Compare with Other Pharmaceutical Innovation Leaders? (Part: II)
Two decades after the introduction of product patents, it is reasonable to ask whether India’s intellectual property ecosystem remains a significant barrier to pharmaceutical innovation. The answer, however, is neither…